Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00080132

Enrollment

Registered

2004-03-25

Start date

2004-10-31

Completion date

2005-04-30

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia

Keywords

HTG, Hypertriglyceridemia, Fredrickson Type I, Hypertriglyceridemia, Fredrickson Type V

Brief summary

The purpose of this study is to determine if implitapide is effective in lowering triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where the maximum tolerable medication and diet were not sufficient.

Interventions

DRUGimplitapide

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

8 Years to 70 Years

Healthy volunteers

Inclusion criteria

In order to participate in this study, patients must meet all of the following inclusion criteria: * be between 8 and 70 years old with diagnosis of Fredrickson Type I or V HTG * be stable on current maximum tolerated triglyceride lowering therapy * have a fasting TG level of at least 880 mg/dL (10 mmol/L) * be male or nonpregnant, nonbreastfeeding female. The women in the study must be surgically sterile, postmenopausal or must practice an effective method of birth control * must be able to give informed consent or if under the age of 18, parents or legal guardians must give their informed consent * meet body weight requirements

Exclusion criteria

* Recent heart attack, coronary artery intervention, coronary bypass surgery, or stroke. * Patients with class 3 or 4 heart failure * Uncontrolled hypothyroidism or other uncontrolled endocrine disease * Known, clinically significant eye abnormalities, such as cataracts * History of hepatic disease or AST or ALT levels greater than 1.5 x ULN at Visit 1 * Alkaline phosphatase greater than 2 times ULN * Serum creatinine greater than 2.0 mg/dL * Liver cirrhosis and severe liver steatosis * Clinically significant infection, malignancy, or psychosis * Use of oral anticoagulants or digoxin unless the dose is stable and is regularly monitored * Participation in any other investigational study within the last 30 days * Breastfeeding or pregnant * Current drug or alcohol abuse * Serious or unstable medical conditions that would compromise the patient's safety or successful participation in the study * Unwillingness to comply with study procedures or unwillingness to cooperate fully

Countries

Netherlands, Norway, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026